ACADIA Pharmaceuticals Files 8-K Report
Ticker: ACAD · Form: 8-K · Filed: 2025-06-10T00:00:00.000Z
Sentiment: neutral
Topics: regulatory-filing, other-events
Related Tickers: ACAD
TL;DR
ACADIA filed an 8-K, no major news yet.
AI Summary
On June 9, 2025, ACADIA Pharmaceuticals Inc. filed an 8-K report to disclose other events. The filing does not contain specific details regarding material events, agreements, or financial transactions beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates that ACADIA Pharmaceuticals Inc. has made a regulatory submission, but it does not provide details on any significant new developments or events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or events.
Key Players & Entities
- ACADIA Pharmaceuticals Inc. (company) — Registrant
- June 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 000-50768 (filing_id) — SEC File Number
- 06-1376651 (tax_id) — IRS Employer Identification No.
- 12830 El Camino Real, Suite 400 (address) — Principal Executive Offices
- San Diego, California (location) — Principal Executive Offices City and State
- 92130 (zip_code) — Principal Executive Offices Zip Code
- (858) 558-2871 (phone_number) — Registrant's Telephone Number
FAQ
What is the purpose of this 8-K filing by ACADIA Pharmaceuticals Inc.?
The 8-K filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' as of June 9, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 9, 2025.
Where is ACADIA Pharmaceuticals Inc. incorporated?
ACADIA Pharmaceuticals Inc. is incorporated in Delaware.
What is the principal executive office address for ACADIA Pharmaceuticals Inc.?
The principal executive office address is 12830 El Camino Real, Suite 400, San Diego, California, 92130.
Does this 8-K filing disclose any specific material agreements or financial transactions?
No, this 8-K filing is categorized under 'Other Events' and does not provide specific details on material agreements or financial transactions within the provided text.
From the Filing
0001193125-25-138452.txt : 20250610 0001193125-25-138452.hdr.sgml : 20250610 20250610160624 ACCESSION NUMBER: 0001193125-25-138452 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250609 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250610 DATE AS OF CHANGE: 20250610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 251037124 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 d73868d8k.htm 8-K 8-K ACADIA PHARMACEUTICALS INC false 0001070494 0001070494 2025-06-09 2025-06-09     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025     Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   000-50768   06-1376651 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   12830 El Camino Real , Suite 400     San Diego , California     92130 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code:  (858)   558-2871 N/A (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On June 9, 2025, Acadia Pharmaceuticals Inc. (the “Company”) announced that the U.S. Court of Appeals for the Federal Circuit (the “Court”) affirmed a decision issued by the U.S. District Court for the District of Delaware in the Company’s Pimavanserin I Cases (as that term is defined in the section titled “Legal Proceedings—Patent Infringement” in Note 9 to the unaudited condensed consolidated financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May